Information: Ergänzungen in die Fach- und Gebrauchsinformation aller -Gemcitabin hältigen Arzneispezialitäten aufnehmen.

Information: Ergänzungen mit folgendem Wortlaut in die Fach- und Gebrauchsinformation aller generischen Gemcitabin - hältigen Arzneispezialitäten aufnehmen.

Further information and amendments to the product information in all EU languages are available on the EMA website.

• attach_file
  Mustertext Gemcitabin | 202 KB
• link
  Link to the EMA Website

Nähere Informationen finden Sie auf der Website der EMA.

Up-to-date information from the 07.11.-11.11.2022 meeting on new approvals, extensions of indication, newly published EPARs and recently started procedures.

Up-to-date information from the 06.11.-09.11.2023 meeting on new approvals, extensions of indication, newly published EPAR's and recently started procedures.

Up-to-date information from the 22.04.-25.04.2024 meeting on new approvals, extensions of indication, newly published EPAR's and recently started procedures.

Up-to-date information from the 14.10.-17.10.2024 meeting on new approvals, extensions of indication, newly published EPAR's and recently started procedures.

Up-to-date information from the 24.02.-27.02.2025 meeting on new approvals, extensions of indication, newly published EPAR's and recently started procedures.

Sponsor Durchgeführt A Randomized, Double-Blind, Placebo- Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic 2021-005790-60/ 2024-5

Referenced at:

• Good Clinical Practice